Malmö, Sweden, February 9, 2022 Acarix submits breakthrough designation request with FDA for heart failure diagnosis  Acarix expands its portfolio and submits a breakthrough designation request for its innovative technology for heart failure diagnosis with the Food and Drug Administration (FDA) in USA. Heart failure affects more than 6 million people in the USA at costs exceeding $30 billion per […]